WO2023025120 - GDF15 FUSION PROTEINS AND USES THEREOF
National phase entry:
Publication Number
WO/2023/025120
Publication Date
02.03.2023
International Application No.
PCT/CN2022/114096
International Filing Date
23.08.2022
Title **
[English]
GDF15 FUSION PROTEINS AND USES THEREOF
[French]
PROTÉINES DE FUSION GDF15 ET LEURS UTILISATIONS
Applicants **
SUNSHINE LAKE PHARMA CO., LTD.
Northern Industrial Area, Songshan Lake
Dongguan, Guangdong 523000, CN
Inventors
YAN, Jiangyu
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
CAO, Rongbo
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
XIAO, Lin
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
ZENG, Junnan
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
HUANG, Limei
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
WEI, Xiling
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
LI, Zhaofeng
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
GONG, Qingwei
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
YAN, Xingguo
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
LI, Jing
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
HUANG, Danxia
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
CHEN, Xiaofeng
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
LI, Wenjia
Dongyangguang Hi-Tech Park, Zhen An Road No. 368, Shang Sha, Chang An Town
Dongguan, Guangdong 523871, CN
Priority Data
202110977378.7
24.08.2021
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1481 | |
| EPO | Filing, Examination | 9211 | |
| Japan | Filing | 592 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 4310 |
Total: 16168 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided are GDF15 fusion proteins and uses thereof. The fusion protein comprises an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. By fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.[French]
L'invention concerne des protéines de fusion GDF15 et leurs utilisations. La protéine de fusion comprend un variant Fc et un domaine actif GDF15, le variant Fc ayant des substitutions d'acides aminés en position 356 et/ou en position 439 de l'IgG Fc selon la numérotation EU et ayant encore la capacité de former un homodimère. Par fusion du variant Fc avec le domaine actif GDF15, la protéine de fusion Fc-GDF15 présente des propriétés physico-chimiques et des niveaux d'expression recombinants significativement améliorés, a une activité in vitro équivalente ou meilleure que les molécules de GDF15 naturelles, et a une demi-vie circulante in vivo significativement prolongée, qui peut supporter la fréquence de dosage d'une fois toutes les deux semaines ou même une fois par mois.